You are here

SM08502 Receives Orphan Drug Designation for Pancreatic Cancer

Data from Phase 1 Study Expected by Summer of 2019

SM08502 (Samumed) has received orphan drug status for the treatment of pancreatic cancer. The oral small-molecule Wnt pathway inhibitor may potentially reduce the expression of genes controlling the differentiation and multiplication of tumor cells.

The drug is currently being evaluated in an open-label, multicenter, dose-escalation phase 1 study (NCT03355066) in 42 adult patients with advanced solid tumors for whom standard therapy is not available. The study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered SM08502 once daily for 28 consecutive days for up to six cycles.

Pancreatic cancer is the fourth leading cause of cancer death in men and women.  Symptoms usually appear during the cancer’s later stages, which contributes to the high mortality rate. In 2018, approximately 55,440 new cases of pancreatic cancer were diagnosed in the U.S. representing 3.2% of all new cancer cases. Around 44,330 deaths from the illness occurred in the same year.

Sources: MPR, January 3, 2019; GlobeNewswire, January 3, 2019

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial